Nano-delivery system for precise long term controlled release of medication for treatment of substance use disorder
|AFFILIATION:||JTP Mesotronix PharmTech, LLC, Austin, Texas, United States|
Track: Medical & Biotech
Tech Readiness: TRL 4
Tech Brief: We propose development of an injectable or implantable nano-delivery system for long term controlled release of medication to facilitate psychological and behavioral therapies in order to treat substance use disorder in veterans and service members.
Value Proposition: Getting our veterans ready for civilian life is as challenging as getting soldiers ready for deployment. Rehabilitation of veterans mentally as well as physically back into the civilian life can take time, money, professional help and much more. Our proposed implantable or injectable drug delivery system (DDS) for long-term release of buprenorphine and potentially its overdose antidote Naloxone can be applied for both pain management and substance use disorder. At low dose level, long-term release of buprenorphine can be used for chronic pain management, with much reduced risks of diversion, overdose and pediatric exposure. At low-to-medium dose, long-term release of buprenorphine can be used for substance use disorder. The “implant and forget” DDS can significantly improve patient compliance to facilitate psychological and behavioral therapies. Based on Probuphine trial results, the implants are more cost effective owing to improved patient compliance and reduced replase rate. Our proposed DDS offers even more than Probuphine in: 30% more buprenorphine capacity per implant; precise control of long-term release rate; potentially lower manufacturing cost; potential to package multiple drugs into one enclosure; and potential to integrate with control electronics for either better control over the drug release or better accommodation of individual differences.
Org Type: Early-stage Startup (Seed)
Booth Number: W509